Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PAVmed (PAVM) Capital Expenditures (2021 - 2025)

PAVmed (PAVM) has 5 years of Capital Expenditures data on record, last reported at $3000.0 in Q3 2025.

  • For Q3 2025, Capital Expenditures changed N/A year-over-year to $3000.0; the TTM value through Sep 2025 reached $21000.0, changed N/A, while the annual FY2024 figure was $55000.0, 77.27% down from the prior year.
  • Capital Expenditures reached $3000.0 in Q3 2025 per PAVM's latest filing, down from $8000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $1.3 million in Q4 2021 and bottomed at $3000.0 in Q2 2024.
  • Average Capital Expenditures over 5 years is $184277.8, with a median of $35500.0 recorded in 2021.
  • Peak YoY movement for Capital Expenditures: surged 1494.44% in 2022, then crashed 97.81% in 2024.
  • A 5-year view of Capital Expenditures shows it stood at $1.3 million in 2021, then plummeted by 76.66% to $298000.0 in 2022, then plummeted by 38.59% to $183000.0 in 2023, then plummeted by 97.81% to $4000.0 in 2024, then decreased by 25.0% to $3000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Capital Expenditures were $3000.0 in Q3 2025, $8000.0 in Q2 2025, and $6000.0 in Q1 2025.